+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane: Mouse lung tissue, Primary antibody: P12359(UCP3 Antibody) at dilution 1/200, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 1 minute    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P12359(UCP3 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using P12359(UCP3 Antibody) at dilution 1/20. (Original magnification: ×200)    

  
  

The UCP3 (Uncoupling Protein 3) antibody is a crucial tool for studying the role of UCP3. a mitochondrial membrane protein primarily expressed in skeletal muscle and brown adipose tissue. UCP3 belongs to the uncoupling protein family, which regulates energy metabolism by dissipating the proton gradient across the mitochondrial inner membrane, thereby reducing ATP synthesis and generating heat. While its exact physiological role remains debated, UCP3 is implicated in fatty acid metabolism, thermogenesis, and protection against oxidative stress by modulating reactive oxygen species (ROS) production.

UCP3 antibodies are widely used in research to detect and quantify UCP3 expression in tissues or cells via techniques like Western blotting, immunohistochemistry, and immunofluorescence. These antibodies help investigate UCP3's involvement in metabolic disorders, such as obesity, diabetes, and mitochondrial dysfunction. Studies also explore UCP3's response to physiological stimuli (e.g., exercise, fasting) or pathological conditions (e.g., insulin resistance).

High-quality UCP3 antibodies are validated for specificity, often through knockout controls, to ensure accurate detection of the ~34 kDa protein. Researchers rely on these tools to clarify UCP3's regulatory mechanisms, including transcriptional control by PPARs (peroxisome proliferator-activated receptors) and post-translational modifications. Ongoing research aims to link UCP3 polymorphisms or altered expression to human metabolic diseases, highlighting its potential as a therapeutic target.